Evolus Stock News

PetIQ (PETQ) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nephros Inc. (NEPH) delivered earnings and revenue surprises of -10% and 1.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its fourth quarter and year end 2021 financial results and provide a business update on Thursday, March 3, 2022.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its fourth quarter and year end 2021 financial results and provide a business update on Thursday, March 3, 2022.

Evolus <> announced on Tuesday that the Australian Therapeutics Good Administration ((TGA)) accepted its submission seeking the regulatory approval of Nuceiva

Evolus Inc (NASDAQ: EOLS) has posted interim Q4 sales of approximately $34.7 million (better than the consensus of $30.87 million), up 68% Y/Y, driven by higher volumes and a higher average selling

Evolus <> has recorded the biggest intraday gain in more than three months after Truist upgraded the Pharma company to Buy from Hold, citing its performance in the Jeuveau launch

Evolus, Inc. (NASDAQ:EOLS) has received a consensus rating of Hold from the nine research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating on the company. The average 12 month price []

During the last session, Evolus Inc. (NASDAQ:EOLS)s traded shares were 0.59 million, with the beta value of the company hitting 2.36. At the end of the trading day, the stocks price was $6.22, reflecting an intraday gain of 6.69% or $0.39. The 52-week high for the EOLS share is $17.38, that puts it down -179.42 Given A -179.42% Drop From High, Can Evolus Inc. (NASDAQ: EOLS) Quickly Recover? Read More »

New Jersey, United States,- Verified Market Research has recently published a research report titled, Flowchart And Diagramming Tools Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used

Initial Draw of $75 Million Expected to Fund Company Beyond Cash Flow Breakeven Second Draw of $50 Million Provides Financial Flexibility for Potential Strategic Transactions NEWPORT BEACH, Calif. --(BUSINESS WIRE)--Dec. 14, 2021-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a